| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Follicular | 20 | 2023 | 587 | 2.930 |
Why?
|
| fas Receptor | 6 | 2015 | 185 | 2.090 |
Why?
|
| Lymphoma, Mantle-Cell | 16 | 2022 | 713 | 1.910 |
Why?
|
| Lymphoma, B-Cell | 12 | 2021 | 895 | 1.780 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 11 | 2023 | 301 | 1.740 |
Why?
|
| Rituximab | 39 | 2023 | 1528 | 1.540 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 19 | 2022 | 1664 | 1.490 |
Why?
|
| Viral Proteins | 6 | 2012 | 435 | 1.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2023 | 15862 | 1.260 |
Why?
|
| Herpesvirus 8, Human | 5 | 2014 | 102 | 1.220 |
Why?
|
| Apoptosis | 17 | 2016 | 7591 | 1.200 |
Why?
|
| Sarcoma, Kaposi | 11 | 2014 | 187 | 1.070 |
Why?
|
| Lymphoma | 11 | 2021 | 1467 | 0.970 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 2 | 2015 | 38 | 0.930 |
Why?
|
| Lymphoma, Non-Hodgkin | 11 | 2021 | 1039 | 0.890 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 2014 | 47 | 0.870 |
Why?
|
| Radioimmunotherapy | 3 | 2020 | 119 | 0.860 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2014 | 182 | 0.820 |
Why?
|
| Hodgkin Disease | 12 | 2021 | 1429 | 0.780 |
Why?
|
| Antibodies, Monoclonal | 16 | 2020 | 4367 | 0.750 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2021 | 2390 | 0.680 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 21 | 2020 | 864 | 0.680 |
Why?
|
| Fas Ligand Protein | 3 | 2015 | 150 | 0.680 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 5 | 2018 | 181 | 0.640 |
Why?
|
| Cyclophosphamide | 17 | 2022 | 3001 | 0.590 |
Why?
|
| Lymphocytes | 3 | 2019 | 1234 | 0.540 |
Why?
|
| Piperidines | 8 | 2023 | 1035 | 0.540 |
Why?
|
| Dendritic Cell Sarcoma, Interdigitating | 1 | 2015 | 4 | 0.540 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 119 | 0.520 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2015 | 17 | 0.520 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 245 | 0.520 |
Why?
|
| Lymphoma, Primary Effusion | 1 | 2014 | 13 | 0.510 |
Why?
|
| Humans | 139 | 2023 | 261506 | 0.490 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 205 | 0.490 |
Why?
|
| Fibroblast Growth Factor 2 | 6 | 1999 | 223 | 0.480 |
Why?
|
| Positron-Emission Tomography | 6 | 2019 | 2173 | 0.480 |
Why?
|
| Methyltransferases | 1 | 2015 | 148 | 0.470 |
Why?
|
| Pyrimidines | 6 | 2020 | 3518 | 0.460 |
Why?
|
| Adenine | 7 | 2023 | 631 | 0.460 |
Why?
|
| Aged | 70 | 2022 | 70117 | 0.460 |
Why?
|
| Fas-Associated Death Domain Protein | 2 | 2012 | 25 | 0.460 |
Why?
|
| Pyrazoles | 5 | 2020 | 1471 | 0.450 |
Why?
|
| Hepatitis C | 4 | 2020 | 524 | 0.450 |
Why?
|
| Hepacivirus | 4 | 2020 | 397 | 0.450 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.440 |
Why?
|
| Antineoplastic Agents | 18 | 2021 | 14289 | 0.430 |
Why?
|
| Treatment Outcome | 42 | 2022 | 32848 | 0.420 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2015 | 551 | 0.420 |
Why?
|
| Middle Aged | 70 | 2022 | 86204 | 0.420 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 3 | 2021 | 119 | 0.410 |
Why?
|
| Male | 82 | 2021 | 123000 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2022 | 10035 | 0.410 |
Why?
|
| RNA-Binding Proteins | 3 | 2013 | 984 | 0.400 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 598 | 0.390 |
Why?
|
| Disease-Free Survival | 24 | 2021 | 10001 | 0.380 |
Why?
|
| Neoplasm Staging | 20 | 2019 | 13658 | 0.380 |
Why?
|
| Adult | 65 | 2022 | 77950 | 0.380 |
Why?
|
| Recurrence | 19 | 2021 | 4758 | 0.360 |
Why?
|
| Vincristine | 12 | 2022 | 1511 | 0.360 |
Why?
|
| Female | 77 | 2021 | 141928 | 0.360 |
Why?
|
| Exanthema | 3 | 2023 | 211 | 0.350 |
Why?
|
| Follow-Up Studies | 26 | 2021 | 14889 | 0.350 |
Why?
|
| Pentostatin | 3 | 2019 | 119 | 0.350 |
Why?
|
| Ribonucleases | 2 | 2000 | 88 | 0.350 |
Why?
|
| Cell Membrane | 1 | 2013 | 850 | 0.350 |
Why?
|
| Doxorubicin | 15 | 2022 | 3005 | 0.350 |
Why?
|
| B-Lymphocytes | 3 | 2013 | 1294 | 0.340 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2022 | 1763 | 0.340 |
Why?
|
| Cytokines | 9 | 2015 | 2809 | 0.340 |
Why?
|
| Hepatitis C, Chronic | 3 | 2019 | 451 | 0.340 |
Why?
|
| Yttrium Radioisotopes | 4 | 2020 | 178 | 0.340 |
Why?
|
| Dexamethasone | 9 | 2021 | 1450 | 0.330 |
Why?
|
| Gene Products, tat | 5 | 2001 | 54 | 0.320 |
Why?
|
| Transfection | 5 | 2015 | 2944 | 0.320 |
Why?
|
| Phosphoproteins | 1 | 2013 | 1152 | 0.300 |
Why?
|
| Neoplasm Grading | 6 | 2021 | 1742 | 0.300 |
Why?
|
| Liver | 2 | 2014 | 2961 | 0.290 |
Why?
|
| Lymph Nodes | 5 | 2019 | 2967 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 6 | 2015 | 6942 | 0.290 |
Why?
|
| Peptides | 1 | 2012 | 1479 | 0.280 |
Why?
|
| Orbital Neoplasms | 2 | 2019 | 224 | 0.280 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 755 | 0.280 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 4557 | 0.270 |
Why?
|
| Interleukin-12 | 2 | 2004 | 253 | 0.270 |
Why?
|
| Neoplasms, Second Primary | 4 | 2019 | 1350 | 0.270 |
Why?
|
| Survival Analysis | 11 | 2021 | 9180 | 0.260 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2021 | 1226 | 0.250 |
Why?
|
| Aged, 80 and over | 29 | 2021 | 29902 | 0.250 |
Why?
|
| Mice | 19 | 2015 | 34495 | 0.250 |
Why?
|
| Survival Rate | 17 | 2021 | 12221 | 0.250 |
Why?
|
| Animals | 26 | 2015 | 59536 | 0.250 |
Why?
|
| Flow Cytometry | 5 | 2014 | 3033 | 0.240 |
Why?
|
| Signal Transduction | 10 | 2016 | 11965 | 0.240 |
Why?
|
| Cell Line, Tumor | 9 | 2020 | 14551 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2016 | 8873 | 0.240 |
Why?
|
| Chorionic Gonadotropin | 3 | 2000 | 130 | 0.240 |
Why?
|
| Salvage Therapy | 6 | 2021 | 2054 | 0.240 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 117 | 0.240 |
Why?
|
| Conjunctival Neoplasms | 2 | 2017 | 120 | 0.230 |
Why?
|
| Neutropenia | 5 | 2021 | 968 | 0.230 |
Why?
|
| Drug Administration Schedule | 12 | 2021 | 3472 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 2027 | 0.230 |
Why?
|
| Remission Induction | 9 | 2018 | 3569 | 0.230 |
Why?
|
| Jurkat Cells | 2 | 2014 | 311 | 0.220 |
Why?
|
| Mice, Transgenic | 5 | 2014 | 4143 | 0.220 |
Why?
|
| Protein Binding | 3 | 2016 | 3438 | 0.220 |
Why?
|
| HIV-1 | 4 | 2001 | 653 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1077 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 3 | 2016 | 361 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 224 | 0.220 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2020 | 113 | 0.210 |
Why?
|
| Hyperplasia | 3 | 2014 | 557 | 0.210 |
Why?
|
| src-Family Kinases | 1 | 2005 | 478 | 0.210 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 2359 | 0.200 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 22 | 0.200 |
Why?
|
| Young Adult | 23 | 2020 | 21445 | 0.200 |
Why?
|
| Bortezomib | 4 | 2018 | 543 | 0.200 |
Why?
|
| Interferons | 3 | 2019 | 291 | 0.190 |
Why?
|
| Cell Proliferation | 6 | 2016 | 7226 | 0.190 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 175 | 0.190 |
Why?
|
| RNA, Messenger | 6 | 2015 | 6150 | 0.190 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 1870 | 0.190 |
Why?
|
| Thrombocytopenia | 3 | 2022 | 846 | 0.190 |
Why?
|
| Thalidomide | 4 | 2015 | 569 | 0.190 |
Why?
|
| Endothelium, Vascular | 4 | 1999 | 891 | 0.190 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2021 | 833 | 0.190 |
Why?
|
| Dermatitis | 1 | 2001 | 60 | 0.190 |
Why?
|
| Monocytes | 2 | 2016 | 788 | 0.190 |
Why?
|
| Bone Marrow Diseases | 2 | 2019 | 177 | 0.190 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 7 | 1991 | 328 | 0.190 |
Why?
|
| NF-kappa B | 3 | 2005 | 1549 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2020 | 86 | 0.180 |
Why?
|
| Hepatitis C Antibodies | 1 | 2020 | 41 | 0.180 |
Why?
|
| Antigens, Ly | 1 | 2000 | 49 | 0.180 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2001 | 187 | 0.180 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.180 |
Why?
|
| Kidney | 1 | 2009 | 2146 | 0.180 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 8865 | 0.180 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 591 | 0.180 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2000 | 136 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2022 | 199 | 0.180 |
Why?
|
| Urine | 1 | 2000 | 143 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2021 | 6207 | 0.170 |
Why?
|
| Cells, Cultured | 4 | 2015 | 5637 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 12 | 5 | 1991 | 185 | 0.170 |
Why?
|
| Sofosbuvir | 1 | 2019 | 22 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 6 | 2013 | 5395 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2020 | 5178 | 0.170 |
Why?
|
| Hematologic Diseases | 3 | 2015 | 242 | 0.170 |
Why?
|
| Growth Inhibitors | 1 | 1999 | 149 | 0.170 |
Why?
|
| Disease Progression | 4 | 2019 | 6682 | 0.170 |
Why?
|
| Methotrexate | 6 | 2022 | 999 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2021 | 1248 | 0.170 |
Why?
|
| Retrospective Studies | 20 | 2022 | 37905 | 0.170 |
Why?
|
| Diphtheria Toxin | 3 | 2007 | 81 | 0.160 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2018 | 31 | 0.160 |
Why?
|
| beta 2-Microglobulin | 2 | 2016 | 184 | 0.160 |
Why?
|
| Capillary Permeability | 1 | 1998 | 114 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2021 | 279 | 0.160 |
Why?
|
| Endothelial Growth Factors | 1 | 1998 | 197 | 0.150 |
Why?
|
| Prognosis | 15 | 2020 | 21713 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 544 | 0.150 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 137 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7789 | 0.150 |
Why?
|
| Lymphokines | 1 | 1998 | 272 | 0.150 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 406 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 6550 | 0.150 |
Why?
|
| Blotting, Western | 3 | 2015 | 3536 | 0.150 |
Why?
|
| Sulfonamides | 2 | 2020 | 1823 | 0.150 |
Why?
|
| Interferon-gamma | 3 | 2015 | 1144 | 0.150 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.150 |
Why?
|
| Antiviral Agents | 3 | 2019 | 1230 | 0.150 |
Why?
|
| Immunotherapy | 2 | 2010 | 3341 | 0.150 |
Why?
|
| Fever | 2 | 2021 | 497 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2021 | 1360 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 750 | 0.140 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 1995 | 362 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 565 | 0.140 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3230 | 0.140 |
Why?
|
| Prednisone | 5 | 2020 | 984 | 0.140 |
Why?
|
| Cell Death | 2 | 2015 | 671 | 0.140 |
Why?
|
| Benzazepines | 1 | 2016 | 108 | 0.140 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2016 | 160 | 0.140 |
Why?
|
| Neutrophils | 2 | 2016 | 835 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2016 | 287 | 0.140 |
Why?
|
| Plasmids | 2 | 2009 | 837 | 0.140 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2015 | 24 | 0.130 |
Why?
|
| Cytarabine | 6 | 2022 | 1973 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2018 | 502 | 0.130 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 63 | 0.130 |
Why?
|
| Sialyltransferases | 1 | 2015 | 23 | 0.130 |
Why?
|
| Hypopituitarism | 1 | 2015 | 33 | 0.130 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 63 | 0.130 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 113 | 0.130 |
Why?
|
| Clone Cells | 1 | 2016 | 555 | 0.130 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2015 | 34 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 528 | 0.130 |
Why?
|
| Neoplasms | 4 | 2019 | 15193 | 0.130 |
Why?
|
| Models, Biological | 2 | 2016 | 3254 | 0.130 |
Why?
|
| Resorcinols | 1 | 2015 | 27 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 112 | 0.130 |
Why?
|
| Bone Marrow | 4 | 2017 | 2358 | 0.130 |
Why?
|
| Culture Media, Conditioned | 4 | 2001 | 260 | 0.130 |
Why?
|
| Phospholipid Ethers | 1 | 2014 | 13 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2016 | 684 | 0.130 |
Why?
|
| Interleukin-2 | 3 | 2007 | 842 | 0.130 |
Why?
|
| Thymocytes | 1 | 2014 | 18 | 0.130 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 81 | 0.130 |
Why?
|
| Vidarabine | 3 | 2017 | 1341 | 0.130 |
Why?
|
| Mice, Nude | 7 | 2000 | 4307 | 0.120 |
Why?
|
| Isoxazoles | 1 | 2015 | 81 | 0.120 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 5 | 2001 | 45 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 1997 | 423 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 247 | 0.120 |
Why?
|
| gamma Catenin | 1 | 2014 | 12 | 0.120 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 146 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 222 | 0.120 |
Why?
|
| Desmosomes | 1 | 2014 | 28 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 3251 | 0.120 |
Why?
|
| Castleman Disease | 1 | 2014 | 69 | 0.120 |
Why?
|
| Antigens, CD19 | 3 | 2022 | 577 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1146 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2014 | 250 | 0.120 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 923 | 0.120 |
Why?
|
| Chromosome Aberrations | 6 | 2005 | 1960 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 4938 | 0.120 |
Why?
|
| Imidazoles | 3 | 2019 | 999 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 196 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 11538 | 0.120 |
Why?
|
| Hematopoiesis | 1 | 2016 | 560 | 0.120 |
Why?
|
| Biopsy | 6 | 2019 | 3443 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 260 | 0.120 |
Why?
|
| 14-3-3 Proteins | 1 | 2014 | 143 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2017 | 612 | 0.110 |
Why?
|
| Prospective Studies | 9 | 2021 | 12873 | 0.110 |
Why?
|
| Adenosine | 1 | 2015 | 289 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 7551 | 0.110 |
Why?
|
| Cell Survival | 3 | 2015 | 3045 | 0.110 |
Why?
|
| Antibodies | 2 | 2006 | 838 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 430 | 0.110 |
Why?
|
| Spleen | 1 | 2014 | 676 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2017 | 1824 | 0.110 |
Why?
|
| Cell Communication | 1 | 2015 | 509 | 0.110 |
Why?
|
| Caspase 8 | 1 | 2012 | 145 | 0.110 |
Why?
|
| Bone Resorption | 1 | 2012 | 138 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 3639 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 184 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 173 | 0.100 |
Why?
|
| Adolescent | 13 | 2021 | 31252 | 0.100 |
Why?
|
| Gene Expression | 4 | 2016 | 3570 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 4 | 2001 | 1547 | 0.100 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 889 | 0.100 |
Why?
|
| Mutation | 7 | 2022 | 15179 | 0.100 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2011 | 51 | 0.100 |
Why?
|
| Mass Screening | 1 | 2020 | 1509 | 0.100 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 4233 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2016 | 4804 | 0.100 |
Why?
|
| Mitoxantrone | 2 | 2017 | 216 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1959 | 0.100 |
Why?
|
| U937 Cells | 1 | 2011 | 171 | 0.100 |
Why?
|
| Conjunctiva | 1 | 2013 | 250 | 0.100 |
Why?
|
| Transplantation Conditioning | 2 | 2012 | 2238 | 0.100 |
Why?
|
| Nitrophenols | 1 | 2011 | 92 | 0.100 |
Why?
|
| Ifosfamide | 3 | 2018 | 344 | 0.100 |
Why?
|
| HL-60 Cells | 1 | 2011 | 302 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2016 | 2979 | 0.100 |
Why?
|
| Weight Loss | 1 | 2015 | 627 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2016 | 2084 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 198 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2012 | 262 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2010 | 503 | 0.090 |
Why?
|
| Molecular Sequence Data | 4 | 2013 | 6089 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1994 | 803 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2015 | 1385 | 0.090 |
Why?
|
| Pseudolymphoma | 1 | 2010 | 22 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 1408 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 194 | 0.090 |
Why?
|
| Myeloablative Agonists | 2 | 2012 | 384 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2005 | 1764 | 0.090 |
Why?
|
| Diarrhea | 3 | 2022 | 686 | 0.090 |
Why?
|
| Eosinophil-Derived Neurotoxin | 2 | 2000 | 8 | 0.090 |
Why?
|
| Time Factors | 7 | 2021 | 12926 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1301 | 0.090 |
Why?
|
| Etoposide | 3 | 2018 | 870 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.090 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 1295 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 1487 | 0.080 |
Why?
|
| Orbital Diseases | 1 | 2010 | 118 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4757 | 0.080 |
Why?
|
| Carboplatin | 3 | 2018 | 823 | 0.080 |
Why?
|
| Polyethylene Glycols | 3 | 2019 | 615 | 0.080 |
Why?
|
| Lung | 2 | 2016 | 3151 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 448 | 0.080 |
Why?
|
| Alleles | 1 | 2014 | 2437 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2012 | 1869 | 0.080 |
Why?
|
| Ferritins | 3 | 2021 | 151 | 0.080 |
Why?
|
| Gene Amplification | 2 | 1990 | 731 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2054 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 4988 | 0.080 |
Why?
|
| Biological Products | 2 | 2021 | 274 | 0.080 |
Why?
|
| Boronic Acids | 2 | 2011 | 362 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 7548 | 0.070 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 1048 | 0.070 |
Why?
|
| Spiro Compounds | 1 | 2007 | 58 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 1443 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 10331 | 0.070 |
Why?
|
| T-Lymphocytes | 4 | 2003 | 3869 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1411 | 0.070 |
Why?
|
| Interleukin-1 | 3 | 1997 | 461 | 0.070 |
Why?
|
| Pyrazines | 2 | 2011 | 495 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2992 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2278 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2007 | 1555 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2011 | 2074 | 0.070 |
Why?
|
| Retreatment | 2 | 2018 | 452 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2005 | 3101 | 0.070 |
Why?
|
| Leukemia | 2 | 2011 | 1635 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2016 | 6915 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 1533 | 0.070 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2021 | 105 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 1242 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2001 | 4654 | 0.060 |
Why?
|
| Edema | 2 | 2015 | 267 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1493 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 7222 | 0.060 |
Why?
|
| Extracellular Matrix | 2 | 1998 | 554 | 0.060 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 2843 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 1678 | 0.060 |
Why?
|
| Genes, tat | 2 | 2001 | 12 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1998 | 1313 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 334 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2021 | 1914 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2009 | 1442 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2020 | 6100 | 0.060 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2003 | 54 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 573 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 210 | 0.060 |
Why?
|
| Skin | 2 | 2001 | 1259 | 0.060 |
Why?
|
| Incidence | 3 | 2018 | 5673 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2008 | 248 | 0.060 |
Why?
|
| COS Cells | 2 | 2001 | 377 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 7702 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 2927 | 0.050 |
Why?
|
| Pregnancy | 5 | 2016 | 7573 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 2015 | 254 | 0.050 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 1489 | 0.050 |
Why?
|
| Cloning, Molecular | 3 | 1994 | 1213 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 3260 | 0.050 |
Why?
|
| Receptors, Transferrin | 2 | 1992 | 45 | 0.050 |
Why?
|
| Fatigue | 3 | 2015 | 1239 | 0.050 |
Why?
|
| Heparan Sulfate Proteoglycans | 2 | 1999 | 54 | 0.050 |
Why?
|
| Vinblastine | 2 | 2012 | 453 | 0.050 |
Why?
|
| Proteins | 2 | 2000 | 1963 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2005 | 889 | 0.050 |
Why?
|
| Bleomycin | 2 | 2012 | 467 | 0.050 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2000 | 22 | 0.050 |
Why?
|
| Angiostatins | 1 | 2000 | 7 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1997 | 1538 | 0.050 |
Why?
|
| Plasminogen | 1 | 2000 | 26 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 249 | 0.050 |
Why?
|
| Paracrine Communication | 1 | 2001 | 128 | 0.050 |
Why?
|
| Endostatins | 1 | 2000 | 48 | 0.050 |
Why?
|
| Pregnancy Proteins | 1 | 2000 | 44 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 392 | 0.050 |
Why?
|
| Iron-Regulatory Proteins | 3 | 1994 | 11 | 0.050 |
Why?
|
| Umbilical Veins | 2 | 1997 | 115 | 0.050 |
Why?
|
| Genes, Viral | 1 | 2000 | 202 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2000 | 109 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 726 | 0.040 |
Why?
|
| DNA Primers | 1 | 2002 | 1399 | 0.040 |
Why?
|
| Receptors, Fibronectin | 1 | 1999 | 25 | 0.040 |
Why?
|
| Mitochondria | 1 | 2007 | 1282 | 0.040 |
Why?
|
| Receptors, Vitronectin | 1 | 1999 | 24 | 0.040 |
Why?
|
| Dacarbazine | 2 | 2012 | 485 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 2000 | 170 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 4320 | 0.040 |
Why?
|
| Simeprevir | 1 | 2019 | 9 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3719 | 0.040 |
Why?
|
| Fluorenes | 1 | 2019 | 17 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2022 | 582 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 57 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 2 | 2015 | 589 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 77 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 198 | 0.040 |
Why?
|
| Genes, ras | 3 | 1991 | 667 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 113 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2002 | 747 | 0.040 |
Why?
|
| Fluorescence | 1 | 1999 | 195 | 0.040 |
Why?
|
| Cell Extracts | 1 | 1998 | 62 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2000 | 875 | 0.040 |
Why?
|
| Valine | 1 | 2019 | 176 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 1998 | 241 | 0.040 |
Why?
|
| Karyotyping | 5 | 1990 | 1022 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1998 | 212 | 0.040 |
Why?
|
| Ribavirin | 1 | 2019 | 178 | 0.040 |
Why?
|
| Melanoma | 1 | 2015 | 5317 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2022 | 1681 | 0.040 |
Why?
|
| Testicular Neoplasms | 3 | 1991 | 529 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 1998 | 157 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2020 | 436 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 1999 | 164 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 1998 | 125 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 600 | 0.040 |
Why?
|
| Biomarkers | 3 | 2019 | 5047 | 0.040 |
Why?
|
| Chromosome Disorders | 2 | 1990 | 417 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 3 | 1990 | 423 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 671 | 0.040 |
Why?
|
| Fibrinolysin | 1 | 1997 | 33 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2022 | 6869 | 0.040 |
Why?
|
| Mitogens | 1 | 1997 | 75 | 0.040 |
Why?
|
| Aspirin | 1 | 2001 | 455 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2000 | 1271 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 30 | 0.040 |
Why?
|
| Risk Factors | 3 | 2020 | 17523 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 521 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Age Factors | 3 | 2014 | 5377 | 0.040 |
Why?
|
| Thrombin | 1 | 1997 | 99 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 1070 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.040 |
Why?
|
| Collagen | 1 | 2000 | 752 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2018 | 587 | 0.040 |
Why?
|
| Depsipeptides | 1 | 2016 | 78 | 0.040 |
Why?
|
| Microcirculation | 1 | 1997 | 200 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 666 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 1998 | 355 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2002 | 1756 | 0.030 |
Why?
|
| Epistaxis | 1 | 2015 | 30 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 202 | 0.030 |
Why?
|
| Cell Count | 1 | 1997 | 508 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| DNA, Neoplasm | 3 | 1990 | 1910 | 0.030 |
Why?
|
| Orbit | 1 | 2017 | 205 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 130 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2014 | 1008 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 428 | 0.030 |
Why?
|
| Abortion, Induced | 1 | 2016 | 91 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 726 | 0.030 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2015 | 32 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1998 | 2488 | 0.030 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 1994 | 1 | 0.030 |
Why?
|
| Iron Regulatory Protein 2 | 1 | 1994 | 3 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2016 | 171 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 259 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 193 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 1391 | 0.030 |
Why?
|
| Lymphocyte Activation | 2 | 1997 | 1688 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2014 | 87 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 125 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1998 | 661 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 9244 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 166 | 0.030 |
Why?
|
| Topotecan | 1 | 2014 | 239 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 348 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1994 | 869 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 2315 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 256 | 0.030 |
Why?
|
| Prednisolone | 1 | 2013 | 123 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1990 | 406 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1586 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 980 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 597 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 333 | 0.030 |
Why?
|
| Cell Division | 2 | 2011 | 2489 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 598 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1995 | 1519 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2864 | 0.030 |
Why?
|
| Alopecia | 1 | 2012 | 126 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 170 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 1618 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 486 | 0.020 |
Why?
|
| Liposomes | 1 | 2013 | 684 | 0.020 |
Why?
|
| Teratoma | 2 | 1990 | 236 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2013 | 375 | 0.020 |
Why?
|
| Infertility, Male | 1 | 2014 | 297 | 0.020 |
Why?
|
| Iron-Binding Proteins | 1 | 1990 | 35 | 0.020 |
Why?
|
| Iron | 2 | 1992 | 376 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 367 | 0.020 |
Why?
|
| Base Sequence | 2 | 1994 | 4917 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 492 | 0.020 |
Why?
|
| Nucleic Acid Renaturation | 1 | 1990 | 6 | 0.020 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2011 | 126 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 634 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4314 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 4744 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 260 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 476 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2016 | 1863 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1990 | 290 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1987 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2011 | 576 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 542 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3981 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 1290 | 0.020 |
Why?
|
| Thionucleotides | 1 | 2008 | 65 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1245 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 641 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2012 | 873 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 155 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2008 | 139 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2352 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 691 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 2138 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3890 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 781 | 0.020 |
Why?
|
| Transaminases | 1 | 2007 | 76 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1990 | 862 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2011 | 1005 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 1990 | 1331 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2012 | 717 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 986 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 6311 | 0.020 |
Why?
|
| DNA | 2 | 1990 | 2693 | 0.020 |
Why?
|
| Monosomy | 1 | 2005 | 95 | 0.020 |
Why?
|
| Hypoalbuminemia | 1 | 2004 | 46 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 369 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5159 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 186 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2004 | 170 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5112 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2004 | 170 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2005 | 234 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 621 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 3976 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1382 | 0.010 |
Why?
|
| Piperazines | 1 | 2011 | 2101 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2008 | 1353 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1990 | 2022 | 0.010 |
Why?
|
| United States | 1 | 2019 | 15433 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 202 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 1544 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 4821 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1992 | 4053 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 1999 | 72 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 1658 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1999 | 300 | 0.010 |
Why?
|
| Carcinoma | 1 | 1991 | 2578 | 0.010 |
Why?
|
| Solubility | 1 | 1999 | 242 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 293 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 3552 | 0.010 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 1997 | 20 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 315 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 1990 | 262 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 2638 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1999 | 429 | 0.010 |
Why?
|
| DNA Damage | 1 | 2005 | 1954 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1999 | 1258 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1995 | 134 | 0.010 |
Why?
|
| Factor VIII | 1 | 1995 | 75 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 1995 | 157 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 15694 | 0.010 |
Why?
|
| G1 Phase | 1 | 1995 | 285 | 0.010 |
Why?
|
| Binding Sites | 1 | 1997 | 2171 | 0.010 |
Why?
|
| Sulfur | 1 | 1992 | 16 | 0.010 |
Why?
|
| Aconitate Hydratase | 1 | 1992 | 20 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 577 | 0.010 |
Why?
|
| Cell Movement | 1 | 1999 | 2466 | 0.010 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1991 | 36 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1995 | 698 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 130 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 354 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1990 | 114 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 217 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1990 | 256 | 0.010 |
Why?
|
| RNA | 1 | 1995 | 1013 | 0.010 |
Why?
|
| Mesonephroma | 1 | 1989 | 17 | 0.010 |
Why?
|
| Gene Library | 1 | 1990 | 294 | 0.010 |
Why?
|
| Cricetinae | 1 | 1990 | 706 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1990 | 321 | 0.010 |
Why?
|
| GTP Phosphohydrolases | 1 | 1990 | 336 | 0.000 |
Why?
|
| RNA, Neoplasm | 1 | 1990 | 771 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1990 | 1471 | 0.000 |
Why?
|
| Placenta | 1 | 1990 | 516 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1990 | 2283 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1990 | 3203 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1989 | 4078 | 0.000 |
Why?
|